TY - JOUR T1 - SIGNIFICANT IMPROVEMENT IN MELANOMA SURVIVAL OVER THE LAST DECADE: A HUNGARIAN NATIONWIDE STUDY BETWEEN 2011–2019 JF - medRxiv DO - 10.1101/2022.04.06.22273390 SP - 2022.04.06.22273390 AU - Gabriella Liszkay AU - Angela Benedek AU - Csaba Polgár AU - Judit Oláh AU - Péter Holló AU - Gabriella Emri AU - András Csejtei AU - István Kenessey AU - Zoltán Polányi AU - Kata Knollmajer AU - Máté Várnai AU - Zoltán Vokó AU - Balázs Nagy AU - György Rokszin AU - Ibolya Fábián AU - Zsófia Barcza AU - Rolland Gyulai AU - Zoltan Kiss Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/04/12/2022.04.06.22273390.abstract N2 - Background Recent real-world studies have reported significant improvements in the survival of malignant melanoma in the past few years, mainly as a result of modern therapies. However, long-term survival data from Central Eastern European countries such as Hungary are currently lacking.Methods This nationwide, retrospective study examined melanoma survival in Hungary between 2011–2019 using the databases of the National Health Insurance Fund (NHIF) and Central Statistical Office (CSO) of Hungary. Crude overall survival and age-standardized 5-year net survival as well as the association between age, sex, and survival were calculated.Results Between 2011 and 2019, 22,948 newly diagnosed malignant melanoma cases were recorded in the NHIF database (47.89% male, mean age: 60.75 years (SD: ±16.39)). 5-year overall survival was 75.40% (women: 80.78%; men: 69.52%). Patients diagnosed between 2017–2019 had a 20% lower risk of mortality compared to patients diagnosed between 2011–2012 (HR 0.80, 95% CI 0.73–0.89; p<0.0001). Age-standardized 5-year net survival rates in 2011–2014 and 2015–2019 were 90.6% and 95.8%, respectively (women: 93.1% and 98.4%, men: 87.8% and 92.7%, respectively). The highest age-standardized 5-year net survival rates were found in the 0–39 age cohort (94.6% in the 2015-2019 period).Conclusion Hungary has similar melanoma survival rates to Western European countries. Based on net survival, the risk of dying of melanoma within 5 years was cut by more than half (55%) during the study period, which coincides with the successful implementation of awareness campaigns and the wide availability of modern therapies.Competing Interest StatementThe authors declare a potential conflict of interest as listed below: Authors ZK, ZP, MV, AB and KK were employed by the company MSD Pharma Hungary. MV, BN and ZV are employees of Semmelweis University. Semmelweis University received a grant from MSD Pharma Hungary to contribute to this research. GyR and IF are employees of RxTarget Ltd. and ZsB is employed of Syntesia Ltd. where their contribution to this project was financially compensated. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.Funding StatementThe authors declare that this study received funding from MSD Pharma Hungary. The funder had the following involvement with the study: in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Medical Research Council in Hungary (Mailing address: 7-8 Szechenyi Istvan ter, Budapest, H-1051, Hungary) gave ethical approval for this work (IV2581-2/2020/EKU).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe raw data supporting the conclusions of this article will be made available by the authors, without undue reservation. ER -